Prothena Corp PLC (PRTA)
57.20
-1.08 (-1.84%)
USD |
NASDAQ |
Feb 07, 16:00
57.22
+0.02 (+0.04%)
After-Hours: 20:00
Prothena Revenue (Quarterly): 1.517M for Sept. 30, 2022
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2022 | 1.517M |
June 30, 2022 | 1.312M |
March 31, 2022 | 1.153M |
December 31, 2021 | 1.172M |
September 30, 2021 | 139.17M |
June 30, 2021 | 60.07M |
March 31, 2021 | 0.16M |
December 31, 2020 | 0.36M |
September 30, 2020 | 0.157M |
June 30, 2020 | 0.195M |
March 31, 2020 | 0.141M |
December 31, 2019 | 0.256M |
September 30, 2019 | 0.205M |
June 30, 2019 | 0.167M |
March 31, 2019 | 0.186M |
December 31, 2018 | 0.194M |
September 30, 2018 | 0.255M |
June 30, 2018 | 0.279M |
March 31, 2018 | 0.227M |
December 31, 2017 | 0.229M |
September 30, 2017 | 0.219M |
June 30, 2017 | 26.81M |
Date | Value |
---|---|
March 31, 2017 | 0.259M |
December 31, 2016 | 0.171M |
September 30, 2016 | 0.286M |
June 30, 2016 | 0.333M |
March 31, 2016 | 0.265M |
December 31, 2015 | 0.307M |
September 30, 2015 | 0.429M |
June 30, 2015 | 0.278M |
March 31, 2015 | 0.593M |
December 31, 2014 | 2.013M |
September 30, 2014 | 1.486M |
June 30, 2014 | 15.12M |
March 31, 2014 | 32.23M |
December 31, 2013 | 0.167M |
September 30, 2013 | 0.171M |
June 30, 2013 | 0.167M |
March 31, 2013 | 0.171M |
December 31, 2012 | 0.575M |
September 30, 2012 | 0.944M |
June 30, 2012 | 0.735M |
March 31, 2012 | 0.404M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.141M
Minimum
Mar 2020
139.17M
Maximum
Sep 2021
10.90M
Average
0.255M
Median
Sep 2018
Revenue (Quarterly) Benchmarks
Mallinckrodt PLC | 465.40M |
Jazz Pharmaceuticals PLC | 940.65M |
Nabriva Therapeutics PLC | 8.784M |
Iterum Therapeutics PLC | -- |
GH Research PLC | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -45.76M |
Total Expenses (Quarterly) | 51.85M |
EPS Diluted (Quarterly) | -0.97 |
Enterprise Value | 2.323B |
Profit Margin (Quarterly) | -3.02K% |
Earnings Yield | -5.84% |
Normalized Earnings Yield | -5.837 |